Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 2/20 | 0.38 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.38 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15328229 | 0.78 | CASP3 (0.49) | GRIN1GRIN2BTRPV1KDM4ELMNA | |
| SCHEMBL7533313 | 0.77 | AHR (0.50) | TRPV1SMYD3CRBNCMA1AHR | |
| SCHEMBL3662896 | 0.72 | CRBN (0.52) | SMN1; SMN2SMYD3CRBNCMA1AHR | |
| SCHEMBL22425175 | 0.70 | GRIN1 (0.56) | GRIN1GRIN2BKMT2ASMN1; SMN2HDAC3 | |
| SCHEMBL260027 | 0.69 | AHR (0.61) | KDM4ELMNAKMT2ASMN1; SMN2HDAC3 | |
| SCHEMBL30648196 | 0.69 | AHR (0.61) | KDM4ELMNAKMT2ASMN1; SMN2HDAC3 | |
| SCHEMBL6543874 | 0.69 | FADS1 (0.50) | TRPV1KMT2AHDAC3HDAC1 | |
| SCHEMBL5843103 | 0.68 | CRBN (0.57) | CRBNCMA1AHREIF2AK2 | |
| Methylamine SCHEMBL28014455 | 0.68 | AHR (0.56) | HDAC3SMYD3CRBNCMA1AHR | |
| SCHEMBL7717893 | 0.68 | AHR (0.59) | KDM4ELMNAKMT2ASMN1; SMN2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Annji Pharmaceutical Co., Ltd. (TW) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281451-A1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ING2, CDK2, MAP3K20 | GRIN1 1939/4885GRIN2B 2859/4885TRPV1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.